Postoperative Radiation Therapy Is Indicated for "Low-Risk" Pathologic Stage I Merkel Cell Carcinoma of the Head and Neck Region but Not for Other Locations
- PMID: 38189056
- PMCID: PMC10767274
- DOI: 10.1016/j.adro.2023.101364
Postoperative Radiation Therapy Is Indicated for "Low-Risk" Pathologic Stage I Merkel Cell Carcinoma of the Head and Neck Region but Not for Other Locations
Abstract
Purpose: The role of postoperative radiation therapy (PORT) in early stage Merkel cell carcinoma (MCC) is controversial. We analyzed the role of PORT in preventing local recurrences (LR) among patients with low-risk, pathologic stage I MCC based on the location of the primary tumors: head/neck (HN) versus non-HN sites.
Methods and materials: One hundred forty-seven patients with MCC were identified that had "low risk" disease (pathologic T1 primary tumor, negative microscopic margins, negative pathologic node status, no immunosuppression or prior systemic therapy). LR was defined as tumor recurrence within 2 cm of the primary surgical bed, and its frequency was estimated with the cumulative incidence method.
Results: Seventy-nine patients received PORT (30 HN, 49 non-HN) with a median dose of 50 Gy (range, 8-64 Gy) and 68 patients were treated with surgery alone (30 HN, 38 non-HN). Overall, PORT was associated with a decreased risk of LR (5-year rate: 0% vs 9.5%; P = .004) with 6 LRs observed in the surgery alone group. Although the addition of PORT significantly reduced LR rates among patients with HN MCC (0% vs. 21%; P = .034), no LRs were observed in patients with non-HN MCC managed with surgery alone. There was no significant difference in MCC-specific survival comparing HN versus non-HN groups, with or without PORT.
Conclusions: For low-risk, pathologic stage I MCC of the extremities and trunk, excellent local control rates were achieved with surgery, and PORT is not indicated. However, PORT was associated with a significant reduction in LRs among low-risk MCC of the HN.
© 2023 The Authors.
Conflict of interest statement
Peter H. Goff reports research funding from Gilead Sciences, Inc, the Conquer Cancer Foundation of the American Society of Clinical Oncology, and the RSNA R&E Foundation not directly related to this work. Daniel S. Hippe reports research grants from GE Health care, Philips Health care, Canon Medical Systems USA, and Siemens Healthineers. Paul Nghiem reports research funding and personal fees from EMD-Serono and Merck & Co. All research funding and personal fees are unrelated to the submitted work.
Figures



Similar articles
-
Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck.Adv Radiat Oncol. 2016 Oct 20;1(4):244-251. doi: 10.1016/j.adro.2016.10.003. eCollection 2016 Oct-Dec. Adv Radiat Oncol. 2016. PMID: 28740894 Free PMC article.
-
Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors.Facial Plast Surg. 2020 Jun;36(3):249-254. doi: 10.1055/s-0039-3401805. Epub 2019 Dec 30. Facial Plast Surg. 2020. PMID: 31887750
-
Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data.Laryngoscope. 2012 Jun;122(6):1283-90. doi: 10.1002/lary.23222. Epub 2012 Apr 20. Laryngoscope. 2012. PMID: 22522673
-
Merkel cell carcinoma: report of 10 cases and review of the literature.J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67. doi: 10.1067/mjd.2000.106505. J Am Acad Dermatol. 2000. PMID: 11050578 Review.
-
Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.Ear Nose Throat J. 2008 Nov;87(11):634-43. Ear Nose Throat J. 2008. PMID: 19006065 Review.
Cited by
-
Merkel Cell Carcinoma.Hematol Oncol Clin North Am. 2024 Oct;38(5):1133-1147. doi: 10.1016/j.hoc.2024.05.013. Epub 2024 Jul 26. Hematol Oncol Clin North Am. 2024. PMID: 39060119 Review.
-
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell Carcinoma.JAMA Dermatol. 2024 May 1;160(5):580-581. doi: 10.1001/jamadermatol.2024.0173. JAMA Dermatol. 2024. PMID: 38506798 Free PMC article. No abstract available.
References
-
- Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. J Cutan Pathol. 2010;37:20–27. - PubMed
-
- Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300–2309. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources